Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Erratum for Sasabe et al., Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.

Sasabe H, Shimokawa Y, Shibata M, Hashizume K, Hamasako Y, Ohzone Y, Kashiyama E, Umehara K.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4431. doi: 10.1128/AAC.01094-16. Print 2016 Jul. No abstract available.

2.

Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.

Sasabe H, Shimokawa Y, Shibata M, Hashizume K, Hamasako Y, Ohzone Y, Kashiyama E, Umehara K.

Antimicrob Agents Chemother. 2016 May 23;60(6):3497-508. doi: 10.1128/AAC.03049-15. Print 2016 Jun. Erratum in: Antimicrob Agents Chemother. 2016 Jul;60(7):4431.

3.

Hemodialysis clearance of iosimenol, a novel iso-osmolar radiographic contrast medium.

Hirao Y, Kashiyama E, Umehara K, Kohno M, Ikei N, Hogstrom B.

Acta Radiol. 2014 Oct;55(8):938-44. doi: 10.1177/0284185113508113. Epub 2013 Oct 12.

PMID:
24123996
5.

Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.

Emoto C, Yoda N, Uno Y, Iwasaki K, Umehara K, Kashiyama E, Yamazaki H.

Curr Drug Metab. 2013 Feb;14(2):239-52. Review.

PMID:
22963393
6.

Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes.

Yoda N, Emoto C, Date S, Kondo S, Miyake M, Nakazato S, Umehara K, Kashiyama E.

Xenobiotica. 2012 Aug;42(8):719-30. doi: 10.3109/00498254.2012.656732.

PMID:
22324396
7.

Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan.

Furukawa M, Umehara K, Kashiyama E.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S83-9. doi: 10.1007/s10557-011-6357-x.

PMID:
22120098
8.

Pharmacokinetic study of the oral administration of procaterol hydrochloride hydrate 50 µg in healthy adult Japanese men.

Kobayashi H, Masuda M, Kashiyama E, Koga N, Yasuda Y, Shibutani T, Endo K, Funaki T, Miyamoto T.

Int J Clin Pharmacol Ther. 2010 Nov;48(11):744-50.

PMID:
20979933
9.

In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.

Shoaf SE, Ohzone Y, Ninomiya S, Furukawa M, Bricmont P, Kashiyama E, Mallikaarjun S.

J Clin Pharmacol. 2011 May;51(5):761-9. doi: 10.1177/0091270010376193. Epub 2010 Aug 2.

PMID:
20679500
10.

Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.

Matsunaga M, Yamazaki H, Kiyotani K, Iwano S, Saruwatari J, Nakagawa K, Soyama A, Ozawa S, Sawada J, Kashiyama E, Kinoshita M, Kamataki T.

Drug Metab Dispos. 2009 Apr;37(4):699-701. doi: 10.1124/dmd.108.026096. Epub 2009 Jan 21.

PMID:
19158312
11.

High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study.

Shimokawa Y, Akiyama H, Kashiyama E, Koga T, Miyamoto G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 5;821(1):8-14.

PMID:
15897016
12.

Functional characterization of single nucleotide polymorphisms with amino acid substitution in CYP1A2, CYP2A6, and CYP2B6 found in the Japanese population.

Iwasaki M, Yoshimura Y, Asahi S, Saito K, Sakai S, Morita S, Takenaka O, Inoda T, Kashiyama E, Aoyama A, Nakabayashi T, Omori S, Kuwabara T, Izumi T, Nakamura K, Takanaka K, Nakayama Y, Takeuchi M, Nakamura H, Kametani S, Terauchi Y, Hashizume T, Nagayama S, Kume T, Achira M, Kawai H, Kawashiro T, Nakamura A, Nakai Y, Kagayama A, Shiraga T, Niwa T, Yoshimura T, Morita J, Ohsawa F, Tani M, Osawa N, Ida K, Noguchi K.

Drug Metab Pharmacokinet. 2004 Dec;19(6):444-52.

13.

Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.

Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MF.

Cancer Res. 2000 Sep 15;60(18):5196-203.

14.

Stereoselective S-oxidation and reduction of flosequinan in rat.

Kashiyama E, Yokoi T, Odomi M, Kamataki T.

Xenobiotica. 1999 Aug;29(8):815-26.

PMID:
10553722
15.

Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.

Kashiyama E, Hutchinson I, Chua MS, Stinson SF, Phillips LR, Kaur G, Sausville EA, Bradshaw TD, Westwell AD, Stevens MF.

J Med Chem. 1999 Oct 7;42(20):4172-84.

PMID:
10514287
16.

Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans.

Kashiyama E, Yokoi T, Odomi M, Funae Y, Inoue K, Kamataki T.

Drug Metab Dispos. 1997 Jun;25(6):716-24.

PMID:
9193873
17.

Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan.

Kashiyama E, Yokoi T, Todaka T, Odomi M, Kamataki T.

Biochem Pharmacol. 1994 Jul 19;48(2):237-43.

PMID:
8053920
18.

Stereoselective S-oxidation of flosequinan sulfide by rat hepatic flavin-containing monooxygenase 1A1 expressed in yeast.

Kashiyama E, Yokoi T, Itoh K, Itoh S, Odomi M, Kamataki T.

Biochem Pharmacol. 1994 Apr 20;47(8):1357-63.

PMID:
8185644
19.

Stereoselective pharmacokinetics and interconversions of flosequinan enantiomers containing chiral sulphoxide in rat.

Kashiyama E, Todaka T, Odomi M, Tanokura Y, Johnson DB, Yokoi T, Kamataki T, Shimizu T.

Xenobiotica. 1994 Apr;24(4):369-77.

PMID:
8059540
20.

Supplemental Content

Loading ...
Support Center